|
ACT1 (NFκB activator 1) |
2.5 |
Confirmed (34) |
Confirmed to be dominant in 10 cancer cell lines (‘epithelial-like’ adherent cancer cells, non-adherent cancer cells, melanomas), but did not examine same normal samples (34) |
Cancer form shown to activate NFκB, but no specific change demonstrated |
|
BIN1 (tumor suppressor) |
1.6 |
Confirmed (18) |
Confirmed in eight melanoma cell lines, compared with fetal melanocytes (normal) (18) |
Eliminates tumor suppressor activity |
|
CC3 (metastasis suppressor) |
0.9 |
Confirmed (35) |
Cancer-specific splice form (TC3) confirmed to be present in all tumor cell lines expressing CC3, versus only very low levels in normal tissues (35) |
Switches CC3 activity from inducing apoptosis to inhibiting apoptosis |
|
FGFR1 (fibroblast growth factor receptor 1) |
0.9 |
Confirmed (36) |
Confirmed in a panel of matched glioblastomas versus normal brain white matter. The level of the cancer-specific form correlated strongly with tumor malignancy (36,37) |
Changes fibroblast growth factor receptor from low-affinity form (normal brain) to high affinity form (tumor) |
|
LDHC (lactate dehydrogenase) |
2.8 |
Confirmed (12) |
Confirmed in a large panel of lung cancer and melanoma samples, versus many normal tissues (12) |
Removes NAD binding |
|
NABC1 (breast carcinoma amplified 1) |
3.2 |
Confirmed (38) |
Observed at higher levels in breast tumors (and not in breast normal) (38) |
Unknown |
| NER (nuclear hormone receptor) |
0.7 |
Confirmed (10) |
Confirmed in 116 of 128 primary cancers and in 31 of 39 cancer cell lines, and absent in the corresponding normal tissues (10) |
Removes DNA binding domain |
